NATCO PHARMA LTD.

Natco Pharma Ltd has announced the designation of two key officials, Mr. Gnanadeva Chalapathy Gudipati as Senior Vice President - Analytical Research & Development and Mr. Madhava Rao Karicherla as Vice President – Formulation Research & Development, Pharma Division, Kothur Unit. These designations are effective from July 6, 2026. The filing details their extensive experience and qualifications, highlighting their contributions to the company's research and development capabilities, particularly in complex formulations and analytical methods. Both individuals bring significant experience from previous roles in the pharmaceutical industry.

Natco Pharma Ltd announced the superannuation of Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division – Kothur. This change will be effective from the closure of business hours on June 30, 2026. Mr. Rao has been a key figure in the company's operations. The filing adheres to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing necessary details regarding the cessation of a senior management role.

Natco Pharma Ltd has announced the closure of its trading window for directors, designated persons, and connected individuals. This restriction will be in effect from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to announce these results will be communicated later. This measure is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, aimed at preventing potential misuse of unpublished price-sensitive information.

Natco Pharma Limited and its alliance partner Lupin Limited have received approval from the United States Food and Drug Administration (U.S. FDA) for their Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection. This injection is a bioequivalent to Eisai, Inc.'s Halaven® Injection. Eribulin Mesylate Injection is indicated for treating metastatic breast cancer and unresectable or metastatic liposarcoma. The reference drug, Halaven®, had estimated annual sales of USD 43.7 million in the U.S. as of April 2026. This approval marks a significant step for both companies in the oncology market.

Natco Pharma Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The results, both standalone and consolidated, were prepared under Indian Accounting Standards (IND-AS) and Regulation 33 of the SEBI Listing Regulations. The Board of Directors approved the results along with amendments to the Corporate Social Responsibility Policy and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. The audit was conducted by BS Rand Co, Chartered Accountants, who issued an unmodified opinion.

Natco Pharma Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The results, both standalone and consolidated, were prepared under Indian Accounting Standards (IND-AS) and Regulation 33 of the SEBI Listing Regulations. The Board of Directors approved the results along with an unmodified opinion from the Statutory Auditors. The company also amended its Corporate Social Responsibility Policy and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Natco Pharma Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026. The trading window for dealing in the company's securities will be closed from May 19, 2026, until 48 hours after the declaration of financial results, as per SEBI regulations.

Natco Pharma Ltd has received a demand notice dated May 12, 2026, from the National Pharmaceutical Pricing Authority (NPPA) for ₹4,92,25,923. The notice alleges overcharging for two drugs between April and November 2023. Natco Pharma reported that there is no material impact on the company's financial or operational activities. The company cited technical issues for the delay in disclosing the information.

Natco Pharma Ltd has received a demand notice dated 12th May, 2026, from the National Pharmaceutical Pricing Authority (NPPA) for ₹4,92,25,923. The notice alleges overcharging for two drugs between April and November 2023. Natco Pharma states that the demand notice will not have a material impact on the company's financial or operational activities.

Natco Pharma Ltd has announced the closure of the trading window for dealing in the securities of the company. The closure is effective from April 1, 2026, and will continue till 48 hours after the declaration of the financial results for the quarter and year ending March 31, 2026. The date of the board meeting for the financial results declaration will be informed in due course.